Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Changzhou Pharmaceutical Factory, received a drug registration certificate for its ezetimibe tablets from China's National Medical Products Administration, according to the company's filing on the Shanghai Stock Exchange.
The pharmaceutical company invested 14.5 million yuan into the research and development of the drug, which is mainly used for disorders, such as primary hypercholesterolemia, homozygous familial hypercholesterolemia and homozygous sitosterolemia, the Thursday filing added.
Price (HKD): $18.75, Change: $-0.17, Percent Change: -0.90%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments